Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 2;2:2055217316665406. doi: 10.1177/2055217316665406

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Likelihood of minor side effects (top row) and serious side effects (bottom row). For all panels, the bars from left to right show the likelihood of side effects on interferon-beta 1a intramuscular, interferon-beta 1b, glatiramer acetate, fingolimod, interferon-beta 1a subcutaneous, dimethyl fumarate, and natalizumab, respectively. Panel A shows the likelihood of minor side effects including all participants. Panel B shows the likelihood of minor side effects including only patients receiving the treatment of interest. Panel C shows the likelihood of serious side effects including all individuals. Panel D shows the likelihood of serious side effects including only participants receiving the treatment of interest.